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1. Introduction  
Inflammatory bowel disease (IBD) consists predominantly of ulcerative colitis (UC) and 
Crohn’s disease (CD), which are clinically distinguished by intestinal localization, local 
features of inflammation, a profile of complications, and familial aggregation. UC is 
characterized by recurring episodes of continuous inflammation limited to the mucosal 
layer of the colon and rectum, and approximately 42% of UC patients have extraintestinal 
complications (Ozdil et al., 2004). This chapter highlights key features of each involved 
organ system including association, diagnosis, and treatment options. 
2. Extraintestinal manifestations of Ulcerative Colitis 
The extraintestinal manifestations (EIMs) of UC can affect any organ system ranging from 
more common ones including the skin and hepatobiliary systems, to less common ones 
including the cardiovascular and renal systems (Das, 1999). Studies have shown that the 
development of one EIM can increase the risk of developing additional complications 
(Monsen et al., 1990). 
2.1 Skin and mucocutaneous complications 
The skin is one of the most commonly affected organ systems in IBD patients. The two most 
common skin disorders associated with UC, erythema nodosum (EN) and pyoderma 
gangrenosum (PG), are reactive due to an immunologic response to UC. Non immunologic 
causes can also occur secondary to nutritional deficiencies and medication side effects. (Das, 
1999; Timani & Mutasim, 2008).  Skin disorders seen in UC caused by malnutrition include 
diseases such as pellagra and cheilitis.  Aphthae are the most common complication of the 
oral mucosa, while fissures and fistulae are most common in the perianal mucosa. 
[FIGURES 1 AND 2] (Areias & Garcia E Silva, 1987). Standard medications used to treat UC 
include steroids and immunosuppressants which can cause skin disorders such as 
cushingoid features and drug eruptions (Timani & Mutasim, 2008). Other disorders, such as 
Sweet’s syndrome and psoriasis have been associated with UC (Timani & Mutasim, 2008).  
2.1.1 Erythema Nodosum 
EN affects about 3% of patients with UC (Areias & Garcia E Silva, 1987; Evans & Pardi, 2007; 
Mir-Madjlessi et al., 1985; Timani & Mutasim, 2008). Lesions affect females with UC more 
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Fig. 1. Fistula with a seton 
 
 
Fig. 2. UC patient with peri-anal fistula (left). Endoscopic view of fistula (right) 
frequently than men and EN rarely precedes the initial diagnosis of UC (Trost & Mcdonnell, 
2005; Weinstein et al., 2005). Typical EN lesions present as painful, raised subcutaneous 
lesions located on extensor surfaces of the extremities (Evans & Pardi, 2007; Timani & 
Mutasim, 2008). However, UC patients almost always have EN lesions on the anterior 
surface of the legs [FIGURE 3] (Mir-Madjlessi, Taylor et al., 1985). The skin nodules are non-
ulcerating and resemble a bruise on the skin (Timani & Mutasim, 2008). Unlike PG, EN 
lesions mirror UC disease activity and worsen with colonic flares (Timani & Mutasim, 2008). 
The average lag time between initial UC diagnosis and appearance of EN is 5 years (Mir-
Madjlessi, Taylor et al., 1985).  
 
 
Fig. 3. EN affecting the lower extremities in a UC patient 
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As EN lesions and UC disease activity usually parallel each other, treatment of the 
underlying UC usually controls the EN lesions. Most lesions are self-limiting, thus a 
conservative approach to therapy is often practiced, such as leg elevation, rest, non-steroidal 
anti-inflammatory drugs (NSAIDs), and potassium iodide (Horio et al., 1981; Marshall & 
Irvine, 1997; Schulz & Whiting, 1976). In situations where lesions occur during quiescent 
phases of UC, treatment with oral steroids is effective. Studies have shown that time to 
remission in patients with EN is approximately 5 weeks which is significantly shorter than 
that seen in PG (Timani & Mutasim, 2008; Tromm et al., 2001). 
2.1.2 Pyoderma Gangrenosum 
The incidence of PG in patients with UC varies between 1.4 and 5% (Areias & Garcia E Silva, 
1987; Mccallum & Kinmont, 1968). PG is more commonly seen in patients with UC as 
opposed to CD, and as with EN, there is a slight female predilection (Bernstein et al., 2001b; 
Greenstein et al., 1976). PG was initially described in 1930 as necrotic ulcers with expanding 
borders of erythema (Newell & Malkinson, 1982). The onset of  noninfectious pustules and 
nodules eventually expand outwards to develop painful shallow and deep ulcers (Callen, 
1998; Farhi & Wallach, 2008). PG usually occurs on the legs, but can also appear anywhere 
on the skin [FIGURE 4]. Pathergy, a phenomenon in which skin lesions develop secondary 
to local trauma, has been reported in approximately 30% of cases of PG (Blitz & Rudikoff, 
2001; Callen, 1998). The average lag time between initial UC diagnosis and appearance of PG 
is 10 years (Mir-Madjlessi, Taylor et al., 1985). Diagnosis of PG is usually clinical, but skin 
biopsy may be necessary for confirmation. PG is classified as a type of neutrophilic 
dermatosis in which the inflammatory infiltrate seen on microscopic examination shows 
dense dermal neutrophilic infiltrates without any evidence of infection (Cohen, 2009; Timani 
& Mutasim, 2008).  Unlike EN, there is no temporal relationship between onset of UC flares 
and the course of PG lesions (Thornton et al., 1980).  
 
 
Fig. 4. PG affecting the lower extremity (left) and face (right) 
In general, the PG lesions are more severe and refractory to therapy than EN. Treatment of 
the underlying UC activity does not always resolve the PG lesions and about 30% of patients 
require additional treatment (Mir-Madjlessi, Taylor et al., 1985).  The mainstay of treating 
PG has been a combination of topical, intralesional, and systemic medications, but no 
specific therapy has proven to be universally effective (Cohen, 2009; Timani & Mutasim, 
2008). Treatments with the best clinical evidence include systemic corticosteroids and 
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cyclosporine as maintenance therapy (Wollina, 2002), assuming there is no concurrent 
infection. Initial doses of oral prednisone have ranged from 0.5 to 2 mg/kg/day and initial 
cyclosporine doses have ranged from 2 to 5 mg/kg/day (Timani & Mutasim, 2008; Wollina, 
2002). Maintaining target trough serum levels of 150-350 ng/ml for cyclosporine has shown 
to be effective in improving PG lesions (Cohen, 2009; Curley et al., 1985; Matis et al., 1992; 
Turner et al., 2010). In small lesions, intralesional steroid injections can be considered 
(Timani & Mutasim, 2008). Other agents including azathioprine, cyclophosphamide, 
methotrexate, high dose intravenous immunoglobulin, mycophenolate mofetil, minocycline, 
plasmapheresis, and hyperbaric oxygen treatment have been employed with variable 
efficacy (Cohen, 2009; Timani & Mutasim, 2008; Tutrone et al., 2007; Wasserteil et al., 1992). 
Biologics including infliximab and adalimumab have also been reported to improve PG 
lesions (Alkhouri et al., 2009; Brooklyn et al., 2006). Additionally, optical treatments such as 
steroids, tacrolimus, benzoyl peroxide, and hydrogen peroxide have shown positive results 
(Callen & Jackson, 2007). To avoid pathergy, unnecessary surgical interventions should be 
avoided. However, surgery can be considered if medical therapies are not successful. Proper 
timing of the surgery with immunosuppressants is essential for optimal long term wound 
stabilization (Rozen et al., 2001; Wittekindt et al., 2007; Wollina, 2002). 
2.1.3 Sweet’s syndrome 
Sweet’s syndrome (SS), also known as acute febrile neutrophilic dermatosis, has a female 
predilection and classically affects women between the ages of 30 and 50 years (Timani & 
Mutasim, 2008). Although the pathogenesis is unclear, Sweet’s syndrome usually develops 
as a response to some type of underlying systemic disease, such as infection, malignancy, 
medications, or IBD (Vij et al., 2010) In fact, studies have shown that patients with SS have 
underlying disease in 50% of cases and an underlying malignancy in 20% of cases (Kemmett 
& Hunter, 1990; Souissi et al., 2007). UC and CD are the most common systemic diseases 
associated with SS (Timani & Mutasim, 2008). SS is characterized by an acute onset of fever, 
leukocytosis, and tender, erythematous plaques that can occur on the extremities, face, neck, 
and trunk (Burrall, 1999; Kemmett & Hunter, 1990; Souissi, Benmously et al., 2007). When 
these lesions occur on the lower extremities, they often resemble EN and skin biopsy may be 
necessary to differentiate the two disease processes (Guhl & Garcia-Diez, 2008). These 
lesions are burning-like and non-pruritic in quality. Other associated symptoms include, but 
are not limited to arthralgia, headache, fatigue, and other constitutional symptoms. Other 
organ systems such as the eye, kidney, liver, and pancreas can be involved as well (Cohen et 
al., 1988). As is also seen with PG, skin biopsy reveals neutrophilic infiltrates in the reticular 
dermis upon histopathological examination (Kemmett & Hunter, 1990; Timani & Mutasim, 
2008). The onset of symptoms from SS usually occur after the initial diagnosis of UC 
(Darvay, 1996). 
The mainstay of treatment for SS is steroids and multiple studies have shown dramatic 
improvement with a 6 week course of systemic corticosteroid therapy (Cohen, Talpaz et al., 
1988; Souissi, Benmously et al., 2007). Topical or intralesional steroids are effective for 
localized disease (Timani & Mutasim, 2008). Recurrence is common and has been reported 
to affect approximately 1/3 of patients (Kemmett & Hunter, 1990). Untreated lesions have 
been reported to heal after variable periods of time, but can be associated with scarring 
(Kemmett & Hunter, 1990; Timani & Mutasim, 2008). Other alternative first line treatments 
include potassium iodide and colchicine. Second line agents including indomethacin and 
clofazimine have been used with successful results, but are not as effective as 
corticosteroids, potassium iodide, and colchicine (Cohen, 2009; Cohen & Kurzrock, 2002). 
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2.1.4 Mucocutaneous manifestations 
Aphthous Stomatitis. About 4.3% of UC patients experience recurrent aphthous stomatitis 
and symptom onset often parallels UC disease activity (Areias & Garcia E Silva, 1987; 
Timani & Mutasim, 2008). Minor aphthous ulcers are small, round, painful, and heal within 
2 weeks without scarring, while major recurrent ulcers are larger, can last for 6 weeks, and 
frequently scar [FIGURE 5] (Ship, 1996; Timani & Mutasim, 2008). A study showed that a 
majority of patients with multiple aphthous ulcers had underlying IBD (Letsinger et al., 
2005). The pathogenesis of aphthous stomatitis and UC is still unclear; studies have not been 
successful in proving that these ulcers are secondary to vitamin deficiencies as the lesions 
did not improve with vitamin therapy (Basu & Asquith, 1980). Treatment options include 
treating the underlying UC, symptomatic relief with steroid elixirs, and systemic treatment 
with steroids and immunosuppressants (Basu & Asquith, 1980; Timani & Mutasim, 2008). 
 
 
Fig. 5. Aphthous stomatitis in a UC patient 
Pyostomatitis Vegetans. Pyostomatitis vegetans, a rare disorder of the oral mucosa, has 
been shown to be a specific marker for IBD, especially UC (Storwick et al., 1994; Timani & 
Mutasim, 2008). Lesions are hyperplastic folds of the mucosa with small abscesses and 
erosions and often manifest before the diagnosis of UC (Hansen et al., 1983). 
Pyostomatitis vegetans is usually resistant to treatments such as topical steroids, antibiotic 
mouthwashes, or hydrogen peroxide. Systemic steroids and immunosuppressants have 
been employed with variable success, but were not always successful in maintaining 
remission (Timani & Mutasim, 2008). In one case report, topical fluocinonide gel resulted in 
temporary state of remission, but total colectomy was necessary to achieve complete 
remission (Calobrisi et al., 1995). 
2.1.5 Miscellaneous skin disorders 
Studies report an increased risk of psoriasis with UC. In one study, of 88 patients with UC, 
5.7% had psoriasis, compared to 1.5% in the control group, suggesting some type of genetic 
relationship between the two (Yates et al., 1982). Another study found an association 
between UC and hidradenitis suppurativa [FIGURE 6]. 
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Fig. 6. UC patient with hidradenitis suppurativa 
2.2 Hepatopancreatobiliary complications 
There are multiple types of hepatic, biliary, and pancreatic complications associated with 
UC. Pancreatic complications are less common than hepatobiliary complications, but will be 
discussed in this section as well given its anatomic location. 
2.2.1 Primary Sclerosing Cholangitis (PSC) 
PSC is a chronic cholestatic liver disease that is caused by progressive inflammatory 
destruction of intra- and extra-hepatic bile ducts, which leads to multifocal biliary strictures, 
resulting in liver cirrhosis and failure. PSC is believed to be the result of a combination of 
genetic and immunological factors, resulting in immune dysfunction and improper 
targeting of the biliary system by lymphocytes and autoantibodies (Bergquist et al., 2008; 
Karlsen et al., 2007; Saarinen et al., 2000). Multiple autoantibodies including ANA, RF and 
atypical p-ANCA have been described in UC and PSC patients (Chapman et al., 2010; 
Terjung & Spengler, 2009). Atypical p-ANCA is detected by indirect immunofluorescence 
staining on ethanol fixed neutrophils in a perinuclear or nuclear pattern whereas classical 
ANCA targets myeloperoxidase and proteinase 3 in a perinuclear pattern (Terjung et al., 
1998). Atypical p-ANCA is detectable in approximately 70% of PSC patients with or without 
UC and is also described in autoimmune hepatitis in patients with IBD (Duerr et al., 1991; 
Saxon et al., 1990; Terjung & Spengler, 2009). Atypical p-ANCA recognizes both beta 
isoform 5 in human neutrophils and bacterial cell division protein FtsZ, which is highly 
conserved across bacterial microflora in the gut (Terjung et al., 2010). This evidence supports 
the theory of a combined pathogenesis of PSC or autoimmune hepatitis in UC.  It is 
proposed that an altered immune response to bacterial antigen in the gut lumen results in a 
"leaky gut” and stimulation of pattern recognition receptors (cross-recognition between 
bacterial antigen in the gut and host components, such as beta isoform 5 in neutrophils) 
which gives rise to autoimmunity phenomenon. (Terjung & Spengler, 2009).  
PSC typically affects young to middle aged males (male to female ratio of 2:1) and while 
only 5% of patients with UC will develop PSC, about 70% to 80% of cases of PSC occur in 
patients with UC (Charatcharoenwitthaya & Lindor, 2006; Lundqvist & Broome, 1997). The 
onset of PSC can precede or follow the onset of UC, and may not be related to UC disease 
activity (Larsen et al., 2010). An isolated alkaline phosphatase level may be the only finding 
during the early stages of the disease, but PSC usually manifests with chronic intermittent 
obstructive jaundice. As the disease progresses, serum bilirubin will rise (Lee & Kaplan, 
1995). In the latter course of the disease, the prothrombin time will be prolonged and serum 
albumin level will decrease, signaling progression to hepatic failure. Other symptoms such 
as right upper quadrant abdominal pain, pruritus, fatigue, fever, and weight loss are 
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variably present. However, PSC should be suspected in asymptomatic patients with an 
isolated elevation of serum alkaline phosphatase (Larsen, Bendtzen et al., 2010).  
Symptomatic patients manifest with icterus, jaundice, hepatomegaly and splenomegaly 
(Chapman, Fevery et al., 2010; Farrant et al., 1991; Wiesner et al., 1989). 
Pericholangitis, described by studies as PSC of the small bile ducts, is another complication 
of UC. A study of 107 patients with UC showed that 35% patients had “small duct” PSC 
compared to 17% with “large duct” PSC, but histologic examinations were indistinguishable 
from each other (Wee & Ludwig, 1985). These findings imply that rather than being separate 
disorders, PSC and pericholangitis merely affect different areas of the same disease process. 
Pericholangitis (or small-duct PSC) is now referred to patients with biochemical and 
histologic characteristics of PSC, but with normal appearing cholangiograms (Wee & 
Ludwig, 1985). Small-duct PSC is more often associated with Crohn's disease whereas large-
duct PSC (classical PSC) is more often associated with UC (Bjornsson et al., 2008; Loftus, 
1997; Rasmussen et al., 1997). Compared to large-duct PSC, small-duct PSC has a relatively 
favorable prognosis with longer transplant-free survival. Approximately 25% of patients 
with small-duct PSC progress to large-duct PSC, but usually does not develop into 
cholangiocarcinoma unless it progresses to large-duct PSC (Bjornsson, Olsson et al., 2008). 
The gold standard for diagnosis is endoscopic retrograde cholangiopancreatography (ERCP) 
and typical radiographic findings include multifocal strictures and dilatation of the intra- 
and/or extra-hepatic biliary tracts, producing a "beaded pattern" (Lee & Kaplan, 1995; 
Maccarty et al., 1983). Recently, magnetic resonance cholangiopancreatography (MRCP) has 
emerged as a non-invasive alternative in diagnosing suspected PSC (Chapman, Fevery et al., 
2010). ERCP may be more preferable over MRCP in diagnosing early stage PSC having a 
specificity and sensitivity near 100% (Angulo et al., 2000; Berstad et al., 2006; Moff et al., 
2006).  However, ERCP does carry potential for significant risks and complications (Larsen, 
Bendtzen et al., 2010). Hence, there has been an increased use of MRCP as an initial 
diagnostic tool, followed by ERCP as needed. If the diagnosis is in doubt, liver biopsy can 
assist in the confirmation of diagnosis as well as staging of disease (Charatcharoenwitthaya 
& Lindor, 2006). However, the classic pathognomonic finding of "onion-skin lesions" or 
periductal concentric fibrosis is rarely seen (Chapman, Fevery et al., 2010). Liver biopsy can 
be essential in the diagnosis of small-duct PSC, but is not required for the diagnosis of large-
duct PSC (Burak et al., 2003; Chapman, Fevery et al., 2010). 
Multiple studies show that using ursodeoxycholic acid (UDCA) at moderate to high dosages 
has been shown to improve liver histology and liver biochemistry (Smith & Befeler, 2007). 
Even though UDCA has not been demonstrated to improve either symptoms or mortality, it 
has been shown to reduce the incidence of colonic dysplasia, colorectal carcinoma and 
cholangiocarcinoma (Pardi et al., 2003). Focus should be on starting these patients early 
enough to delay progression to cirrhosis, cholangiocarcinoma, and death. This is especially 
important as UDCA is not as effective in patients with end stage PSC. During treatment 
with UDCA, stenosis of bile ducts may occur and endoscopic intervention with dilatation 
has been showed to be effective (Stiehl, 2004). At the present time, liver transplantation is 
the only effective treatment especially for end-stage PSC or PSC with cholangiocarcinoma 
(Chapman, Fevery et al., 2010; Navaneethan & Shen, 2010). Orthotopic liver transplantation 
is the established treatment in PSC with 85% to 90% of 5-year survival rate (Gow & 
Chapman, 2000). However, 20 to 25% of transplanted patients develop recurrent PSC 5 to 10 
years after transplant (Alabraba et al., 2009; Campsen et al., 2008; Graziadei et al., 1999; 
Navaneethan & Shen, 2010). 
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2.2.2 Malignancies 
PSC has been shown to be complicated by malignancies including cholangiocarcinoma (CCA), 
bile duct carcinoma, gall bladder carcinoma, and hepatocellular carcinoma.  Studies have 
shown that patients with UC and PSC are more prone to develop cholangiocarcinoma, 
colorectal cancer, gallbladder cancer and hepatocellular carcinoma (Broome et al., 1995; Florin 
et al., 2004; Kitiyakara & Chapman, 2008). Typically CCA presents as an intraductal tumor, 
and at times can be quite difficult to differentiate from a benign PSC stricture [FIGURE 7]. 
Evidence supporting diagnosis of CCA include high levels of CA 19-9, cross sectional liver 
imaging with long, confluent strictures and ERCP with brush biopsy of strictures, in addition 
to overall clinical presentation (Chapman, Fevery et al., 2010; Charatcharoenwitthaya et al., 
2008; Levy et al., 2005). The relative risk of bile duct carcinoma in UC patients is 31.3 compared 
to the general population and the prognosis is quite poor with a mean survival of less than one 
year.  PSC and pericholangitis are common pre-existing lesions in UC patients with bile duct 
carcinoma (Mir-Madjlessi et al., 1987).  A case report recommended that in patients with UC 
and PSC with abnormal gallbladders, liver biopsy and cholecystectomy should be performed 
(Dorudi et al., 1991). Another case report documented an association between fibrolamellar 
hepatocellular carcinoma and UC complicated by PSC (Snook et al., 1989). 
 
 
Fig. 7. ERCP of a UC patient with PSC showing high grade strictures within the right and 
left hepatic ducts with secondary pronounced intrahepatic ductal dilatation 
2.2.3 Primary Biliary Cirrhosis (PBC) 
PBC is autoimmune in nature with the unique presence of anti-mitochondrial antibodies 
(AMA) on laboratory testing. Studies have reported that in patients with UC, there is a 30 
fold risk of primary biliary cirrhosis compared to the general population (Koulentaki et al., 
1999). UC patients with PBC, as compared to patients without UC, are younger and more 
likely to be male. The mainstay treatment of PBC includes cholestyramine to relieve itching 
by reducing the amount of bile acid in the blood, UDCA to increase bile flow to reduce 
inflammation in bile ducts, fat soluble vitamins for nutritional supplementation, and ERCP 
for bile drainage. Ultimately, advanced PBC with liver failure and portal hypertension 
requires liver transplantation. 
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2.2.4 Autoimmune Hepatitis (AIH) 
Autoimmune chronic active hepatitis (CAH) has been observed in UC patients with and 
without PSC (Rabinovitz et al., 1992; Snook, Kelly et al., 1989). In addition to laboratory tests 
showing the presence of autoantibodies, such ANA and anti-smooth muscle muscle 
antibody (ASMA) and abnormal liver function tests, liver biopsy may be necessary to 
confirm the diagnosis (Alvarez et al., 1999). In patients with both UC and autoimmune 
hepatitis, up to 42% have abnormal cholangiographic findings indicating the coexistence or 
overlap of PSC (Perdigoto et al., 1992). UC patients with both AIH and PSC respond 
relatively poorly to immunosuppression and progress more rapidly to cirrhosis. 
Autoimmune CAH responds to steroids, but in the presence of PSC, dual therapy with 
steroids and azathioprine is indicated (Perdigoto, Carpenter et al., 1992; Rabinovitz, 
Demetris et al., 1992). Thus, in patients with UC complicated by autoimmune CAH, 
cholangiography is necessary to rule out PSC to dictate further therapy. 
2.2.5 Other hepatic complications 
Fatty liver or hepatic steatosis can be observed in UC patients and appears to correlate with 
disease severity or duration and may contribute to abnormal liver function tests (Riegler et 
al., 1998). The ultrasound findings of fatty liver show hepatomegaly and a dysechogenic 
pattern (De Fazio et al., 1992). Causes of fatty liver include malnutrition, protein loss, and 
steroid use. Patients are usually asymptomatic and treatment is geared towards treatment of 
the underlying UC and improving nutritional status (Navaneethan & Shen, 2010). 
Hepatic amyloidosis is an extremely rare complication of UC (0.07% vs. 0.9% in CD) and 
control of gut inflammation can reduce amyloid deposition severity (Greenstein et al., 1992; 
Navaneethan & Shen, 2010; Wester et al., 2001). Because of the rarity and asymptomatic 
nature of this complication, the need for liver biopsy remains unclear and should be made 
on a case-by-case basis. 
Hepatic and/or splenic abscesses are rare complications of IBD and even more rare in UC. 
They are diagnosed by ultrasound or CT scan showing non-enhancing hypodense lesions in 
the liver and/or spleen. Clinical suspicion of hepatosplenic abscesses should be considered 
in febrile patients with IBD whose presentations are inconsistent with IBD exacerbation. The 
treatments of hepatosplenic abscesses include drainage, broad-spectrum antibiotics, and 
treatment of underlying IBD with sulfasalazine and/or steroids. The pathogenesis of 
hepatosplenic abscess in UC is unclear at this time with possible mechanisms including 
infectious and immunologic etiologies (Navaneethan & Shen, 2010). 
2.2.6 Portal vein thrombosis 
Portal vein thrombosis is considered an EIM of UC and is thought to be secondary to 
coagulation abnormalities caused by chronic bowel inflammation. Ulceration of the mucosa 
barrier can increase the chance of gut microbial translocation and thus portal vein 
thrombosis (Navaneethan & Shen, 2010). Portal vein thrombosis has also been observed in 
UC patients who were status post proctocolectomy (Navaneethan & Shen, 2010). 
2.2.7 Pancreatic complications 
Patients with UC have increased chances of developing both acute and chronic pancreatitis 
(Keljo & Sugerman, 1997). Causes include idiopathic, gallstones, PSC, and medication side 
effects from drugs such as 5-ASA, mesalamine, corticosteroids, azathioprine, and 6-
mercaptopurine. Medication induced pancreatitis does not lead to chronic pancreatitis and 
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treatment involves cessation of the insulting drug (Bank & Wright, 1984). On the other hand, 
the etiology of chronic pancreatitis is unknown. Chronic pancreatitis with UC is usually 
painless, but is associated with pancreatic duct strictures and severe pancreatic exocrine 
insufficiency (Pena et al., 2000). 
Autoimmune pancreatitis (AIP) is a less common complication of UC compared to drug-
induced or gallstone pancreatitis (Navaneethan & Shen, 2010). It affects elderly individuals 
and can present with obstructive jaundice. Steroids have become the standard treatment of 
AIP for obstructive jaundice, abdominal pain, and prevention of future episodes of 
pancreatitis (Finkelberg et al., 2006; Kamisawa et al., 2009). Failure to respond to steroids 
raises the possibility of pancreatic cancer and warrants further work up for malignancy. 
2.3 Musculoskeletal complications 
Musculoskeletal complications are quite common and affect approximately 25% of all IBD 
patients (Bourikas & Papadakis, 2009; Danese et al., 2005). The musculoskeletal involvement 
of UC patients can be divided into the following categories: 
1. Arthritis: peripheral arthritis, axial arthritis including ankylosing spondylitis (AS) and 
sacroiliitis  
2. Periarticular inflammation: enthesitis, tendonitis, dactylitis, clubbing, periostitis, 
myositis, fibromyalgia, and granulomatous lesions of the joint and bone 
3. Metabolic bone disorders: osteoporosis, osteopenia, osteonecrosis 
4. Localized myopathy: orbital myositis, gastrocnemius myalgia syndrome, polymyositis, 
dermatomyositis 
5. Impaired growth: seen in children and adolescents 
2.3.1 Arthritis 
Peripheral Arthritis: Arthritis, located peripherally or axially, can precede, occur 
concurrently, or follow the diagnosis of UC (Bourikas & Papadakis, 2009). The type of 
articular involvement in UC is inflammatory and is associated with pain, heat, swelling, and 
decreased joint mobility. Similar to rheumatoid arthritis (RA), the pain and stiffness of 
arthritis in UC is worse in the morning and improves with physical activity. However, unlike 
RA arthritis, UC arthritis is typically seronegative, non-deforming, and non-erosive. The 
peripheral arthropathy seen with UC can be classified into two types: Type 1 and Type 2 
(Atzeni et al., 2009; Bourikas & Papadakis, 2009; Brakenhoff et al., 2010; Jose & Heyman, 2008). 
Type 1 is pauci-articular, asymmetrical in distribution, and typically affects less than 5 large 
joints, such as the knees, elbows, and ankles. The risk of developing peripheral arthritis is 
higher in UC patients and increases with colonic involvement (Bourikas & Papadakis, 2009; 
Jose & Heyman, 2008). The risk of developing type 1 peripheral arthritis is also increased 
with the presence of other EIMs, such as EN, PG, abscesses, stomatitis, and uveitis (Jose & 
Heyman, 2008). With the exception of small joints or type 2 polyarticular arthritis, the 
arthritis usually correlates with UC disease activity (Atzeni, Ardizzone et al., 2009). This type 
of arthritis is sometimes referred to as colitic arthritis, affects up to 20% of UC patients, and 
usually presents as an acute self-limiting episode that lasts less than 10 weeks with a median of 
5 weeks (Bourikas & Papadakis, 2009; Das, 1999; Jose & Heyman, 2008). However, about 20% 
to 40% will experience recurrent episodes of arthritis.  
Type 2 arthropathy is typically polyarticular, involving 5 or more joints including the small 
joints of the hands, and most commonly affects the MCP joints of the hands. This type of 
polyarticular arthritis with IBD is associated with uveitis, but not with other EIMs of IBD. 
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Unlike type 1 arthritis, symptoms of type 2 arthritis are independent of bowel disease 
activity and can persist for months to years with a median of 3 years (Bourikas & Papadakis, 
2009; Jose & Heyman, 2008). Genetic factors implicated in the association between 
peripheral arthritis and UC include: HLA-B27, HLA-B35, HLA-DR, and HLA-B44 
(Brakenhoff, Van Der Heijde et al., 2010). 
Axial Arthritis: Axial arthritis, referred as type 3 arthritis, includes both AS and isolated 
sacroiliitis. This axial type of arthropathy occurs less frequently than peripheral arthritis, 
and as with type 2 arthropathy, does not parallel the underlying IBD in clinical course 
(Bourikas & Papadakis, 2009; Brakenhoff, Van Der Heijde et al., 2010; Jose & Heyman, 2008). 
In fact, studies have shown that axial arthropathy often precedes UC diagnosis by several 
years (Bourikas & Papadakis, 2009). In fact, studies have shown that AS occurs in 
approximately 5% to 10% of patients with IBD and patients are typically young and HLA-
B27 positive [FIGURES 8 AND 9]. Presentation involves a severe onset of back pain with 
morning stiffness that is exacerbated by activity. Spondyloarthritis commonly coincides 
with periarticular involvement including synovitis, dactylitis, enthesitis, plantar fasciitis, 
and chest wall pain (Bourikas & Papadakis, 2009). Sacroiliitis seen with UC is often 
asymptomatic, but can manifest as pelvic pain that improves with movement and sacroiliac 
joint pain worsened with pelvic brim pressure [FIGURE 10] (Atzeni, Ardizzone et al., 2009). 
 
 
Fig. 8. X-Rays of a UC patient with AS 
 
 
Fig. 9. MRI images (Sagittal, left and coronal, right) showing AS in a young patient with UC 
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Fig. 10. MRI showing right sided SI and fused left sided joint space 
Treatment: The treatment of UC-associated arthropathies is extrapolated from other forms 
of arthritis (Atzeni, Ardizzone et al., 2009). As with other types of UC EIMs, treatment of the 
underlying disorder with medical and/or surgical interventions can improve the peripheral 
arthritis seen with UC (Danese, Semeraro et al., 2005; Jose & Heyman, 2008). Symptomatic 
treatments include rest, physical therapy, and intra-articular steroid treatments. A short 
course of celecoxib (COX-2 inhibitor) for 2 weeks has been safely used to treat arthritis in 
UC (Sandborn et al., 2006). Patients failing to improve should be considered for second-line 
therapy, including sulfasalazine and immunomodulators (Danese, Semeraro et al., 2005). In 
patients with active colonic inflammation and peripheral arthritis, biologic agents such as 
infliximab should be considered (Atzeni, Ardizzone et al., 2009). 
In contrast to peripheral arthritis which generally responds to treatment of the colitis, 
medical and surgical therapy of the underlying bowel disease does not affect the disease 
course of axial arthropathy. Traditionally, mainstay treatments of AS included intensive 
physical therapy plus disease-modifying drugs such as sulfasalazine and methotrexate 
(Atzeni, Ardizzone et al., 2009). However, recent studies have shown that TNF-alpha 
inhibitor agents such as infliximab are effective in treating AS, IBD, and IBD-associated 
peripheral and axial arthritis (Atzeni, Ardizzone et al., 2009; Bourikas & Papadakis, 2009; 
Danese, Semeraro et al., 2005).  
2.3.2 Periarticular Inflammation 
Periarticular inflammation including enthesitis, tendonitis, clubbing, dactylitis, periostitis, 
fibromyalgia, and granulomatous lesions of the joints and bones, have been described in UC 
patients in the presence and absence of arthritis (Bourikas & Papadakis, 2009; Salvarani et 
al., 2000). These types of periarticular involvement usually do not alter inflammatory 
markers, but can severely compromise quality of life. 
2.3.3 Metabolic bone disorders 
Bone disorders such as osteoporosis, osteopenia, and osteonecrosis are associated with UC 
and this relationship is intensified with concomitant steroid use (Jose & Heyman, 2008). 
Some studies have shown that in IBD patients, the prevalence rate of osteoporosis can range 
from 2% to 30% and as high as 40% to 50% for osteopenia (Danese, Semeraro et al., 2005). 
However, there is still controversy on the exact relationship between UC and osteoporosis. 
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While one study found approximately 25% of UC patients to have decreased bone mineral 
density (BMD), another group in Norway found that unlike CD patients, UC patients had 
relatively normal body compositions without significantly decreased body mass index 
(BMI) or BMD (Jahnsen et al., 1997; Jahnsen et al., 2003; Vestergaard, 2004).  
The exact pathogenesis between UC and metabolic bone disorders is not entirely clear, but 
suggested causes include nutritional deficiency, malabsorption of calcium and vitamin D, 
steroid use, immobility, and elevated inflammatory cytokines (Danese, Semeraro et al., 
2005). Consequently, calcium and vitamin D levels should be checked in UC patients taking 
steroids. Attempts to minimize steroid dosage and/or duration, substituting steroids with 
steroid-sparing immunomodulators, or supplementation with bisphosphonates or calcitonin 
can prevent bone loss and reduce morbidity in these patients (Jose & Heyman, 2008). 
Osteonecrosis, also known as aseptic or avascular necrosis, is characterized by bone tissue 
death secondary to poor vascular supply. Believed to be the result of ischemia of the juxta-
articular bone, osteonecrosis has been described in both children and adults with IBD with a 
prevalence of <1% of all IBD patients and up to 4% of patients taking steroids (Jose & 
Heyman, 2008; Madsen & Andersen, 1994). Osteonecrosis is a serious complication of UC 
that should be diagnosed early by magnetic resonance imaging and/or bone scan to prevent 
serious complications (Madsen & Andersen, 1994). Treatment includes medical 
management with calcium, vitamin D, bisphosphonates, hydrochlorothiazide, or anti-
hypertensive to reduce bone edema. Surgical options include core-decompression biopsy, 
arthroplasty, or joint replacement (Jose & Heyman, 2008).  
2.3.4 Localized myopathy 
Muscle involvement is a rare EIM and UC patients are less affected than CD (Bourikas & 
Papadakis, 2009). The myopathy seen in UC patients can be a direct result of the underlying 
autoimmune disorder or a side effect of the IBD therapy. In most patients, diagnosis of IBD 
usually precedes the development of myopathy symptoms. Myopathy disorders that have 
been associated with UC include orbital myositis, gastrocnemius myalgia syndrome, 
polymyositis, and dermatomyositis (Bourikas & Papadakis, 2009). Orbital myositis in UC 
patients is rare and only a handful of cases have been reported (Macarez et al., 2005). It 
presents as acute orbital pain, diplopia, eyelid swelling, exophthalmos, and conjunctival 
injection. Diagnosis is made by CT or MRI that can show proptosis and extra-ocular muscle 
swelling. A case report documented successful results with a short course of systemic 
steroids and long-term mesalamine therapy (Macarez, Bazin et al., 2005). Gastrocnemius 
myalgia syndrome usually presents as calf tenderness and is less commonly reported in UC 
compared to CD. Polymyositis and dermatomyositis in UC patients usually present with 
proximal muscle weakness (Bourikas & Papadakis, 2009). Diagnostic work up should 
include CPK, ESR, muscle/skin biopsy, and EMG. Mainstay treatment of the various types 
of myositis should always include glucocorticoids. TNF-alpha blockers may be required for 
orbital myositis and azathioprine for polymyositis and dermatomyositis (Bourikas & 
Papadakis, 2009). A case report of an elderly woman with UC and polymyositis who was 
treated with corticosteroids and 5-ASA had marked improvement of her muscle weakness 
(Chugh et al., 1993).  
2.3.5 Impaired growth 
About 33% of patients with IBD develop symptoms during childhood and adolescence 
(Ballinger et al., 2001). Of this young population, approximately 28% of UC patients have 
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evidence of growth impairment and delay with onset of bowel symptoms (Berger et al., 
1975; Stawarski et al., 2006). The underlying UC causes of this chronic under-nutrition 
include poor oral intake from fear of colitis exacerbation, malabsorption from inflammation, 
and hypoalbuminemia secondary to protein-losing enteropathies (Jose & Heyman, 2008). 
There is evidence that inflammatory cytokines such as IL-6 and TNF-alpha account for the 
chronic inflammation that impairs linear growth and thus development (Ballinger, 
Camacho-Hubner et al., 2001). Studies have also shown that high dose daily steroid therapy 
is associated with diminished type 1 collagen production, which is also important for linear 
growth. Interestingly, low dose and alternate-day steroid regimens have less dramatic 
impacts on growth velocity and should be considered as treatment regimens for UC (Berger, 
Gribetz et al., 1975). Height, weight, puberty staging, and bone age should be regularly 
checked in young UC patients to prevent poor development. Optimal management of these 
young patients involves a balance between selecting an appropriate regimen that adequately 
treats the UC while minimally compromising normal growth and development. Ideally, 
keeping the underlying bowel disease in remission, especially during puberty, can improve 
the chance of reaching full growth potential. Calorie supplementation and enteral nutrition 
should be utilized to meet individualized nutritional goals. (Ballinger, Camacho-Hubner et 
al., 2001). Surgical interventions eradicating medically refractory disease activity have had 
more success in reversing growth retardation than high dose steroids, assuming that there 
was not a significant preexisting delay (Berger, Gribetz et al., 1975). 
2.4 Ocular complications 
Ocular complications associated with UC were first described in 1925 in two patients with 
corneal inflammation and conjunctivitis (Crohn, 1925). A large study of 465 UC patients 
showed that 17 patients (3.6%) had ocular involvement. Of these 17 patients, 7 patients had 
episcleritis and 5 had iritis or anterior uveitis (Billson et al., 1967). Two patients had 
blepharo-keratitis and there were single cases of interstitial keratitis, choroiditis, and 
dacryocystitis reported in this study.  Episcleritis, uveitis and conjunctivitis are the most 
frequent eye manifestations of IBD. Females are affected more frequently than males and 
eye manifestations were found to be well correlated with UC flares (Billson, De Dombal et 
al., 1967). Another study reported a higher incidence with 10 out of 78 UC patients (12.8%) 
having ocular complications (Ozdemir et al., 2000). 
2.4.1 Episcleritis 
The episclera is the connective tissue between the conjunctiva and sclera. Episcleritis is thus 
defined as an inflammation of the episclera and its adjacent tissues. The inflammation is 
usually segmental and bilateral in distribution and associated with eye discomfort, 
irritation, redness, and tearing [FIGURE 11]. However, there is usually no visual impairment 
or purulent discharge. Episcleritis responds well to topical steroids (Billson, De Dombal et 
al., 1967). 
2.4.2 Uveitis 
The uvea is the middle layer of the eye and is situated between the retina and sclera. It 
includes the iris, ciliary body, and the choroid of the eye. Uveitis refers to an inflammation 
of the uvea. Multiple studies and case reports have demonstrated that UC can be associated 
not only with anterior uveitis, but also posterior, peripheral, or even pan-uveitis (Ozdemir et 
al., 2000). Symptoms of uveitis include photophobia, blurred vision, pain, and conjunctival 
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injection. Anterior uveitis or iritis is distinguished from other causes of red eye by slit lamp 
examination and leukocytes seen in the anterior chamber is diagnostic of anterior uveitis. 
Posterior uveitis can be diagnosed by one of two ways: either by direct visualization of the 
active chorioretinal inflammation and/or by detecting leukocytes in the vitreous humor by 
slit lamp or indirect ophthalmoscope. Uveitis usually responds to topical steroid treatment. 
Severe cases of iritis should be treated with mydriatics to dilate pupils to prevent synechia, 
in which there is adhesion of the iris to the cornea or lens. It has been speculated that 
primary treatment of the UC with systemic steroids could account for the relatively low 
incidence of uveitis in patients with UC (Billson, De Dombal et al., 1967). 
 
 
Fig. 11. UC Patient with episcleritis 
2.4.3 Scleritis 
UC has been associated with different types of anterior scleritis: diffuse, nodular, and 
posterior scleritis (Ozdemir et al., 2000). Symptoms of scleritis include deep eye pain with 
radiation to eyebrows, cheeks and temples, eye redness, tearing, photophobia and blurred 
vision. Severe cases can ultimately lead to blindness. Initial treatments include NSAIDs; oral 
steroids or immunosuppressants may be necessary for advanced disease. Necrotizing 
scleritis, the most severe form of scleritis, causes severe inflammation and pain in part of or 
the entire sclera. This serious disorder is associated with RA, but has also been reported in 
UC (Lyne & Pitkeathley, 1968). A case report documented a case of severe necrotizing 
scleritis in a patient with UC that was surgically treated with an amniotic membrane graft 
and successfully preserved the patient’s vision (Lazzaro, 2010). 
2.4.4 Optic neuritis 
Optic neuritis is inflammation of optic nerve and studies have shown that optic neuritis can 
be the sole ocular manifestation of UC (Sedwick et al., 1984). Patients with UC who develop 
rapid and progressive reduction in vision should be suspected to have optic neuritis. 
Untreated optic neuritis can lead to permanent loss of vision and treatment of optic neuritis 
typically includes systemic steroid (Nakamura et al., 2005). 
One of the key inflammatory mediators of UC includes the cytokine tumor necrosis-alpha 
(TNF-α). As such, anti-TNF-α therapies are often used to treat patients with UC and are 
generally well tolerated (Rutgeerts et al., 2005). However, there have been reports of the 
development of demyelinating disease such as optic neuritis in patients receiving anti-TNF-
α therapy (Nash & Florin, 2005). A study of 15 patients who presented with optic neuritis 
following TNF-α antagonist therapy showed that 9 of these patients experienced full 
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recovery, 2 had partial resolution, and 4 patients continued to be symptomatic (Simsek et al., 
2007). It is recommended that patients on anti-TNF-α therapy should be monitored for signs 
and symptoms of optic neuritis and if symptomatic, should have the medication discontinued.  
2.4.5 Other ocular complications 
Other ocular complications include marginal keratitis and corneal ulcers, cataracts, recurrent 
conjunctivitis, blepharitis, retinal vasculitis, retinal vein occlusion, and neuroretinitis 
(Billson, De Dombal et al., 1967). 
In summary, routine eye examinations are recommended for UC patients. Early diagnosis 
and treatment of ocular involvement can prevent serious and potentially irreversible 
complications of UC.  
2.5 Hematologic and vascular complications 
Hematological complications that are associated with UC include (Gomollon & Gisbert, 
2009; Imagawa, 1999; Wilson et al., 2004): 
1. Anemia of various causes: iron deficiency anemia (IDA), anemia of chronic disease 
(ACD), folic acid or B12 deficiency, megaloblastic anemia, autoimmune hemolytic 
anemia, or anemia secondary to marrow-suppressing medications. 
2. Granulocytopenia, thrombocytopenia 
3. Idiopathic thrombocytopenic purpura 
4. Neoplastic (rare): myelodysplastic syndrome, acute or chronic leukemia 
In IBD, the prevalence of anemia ranges from 8.8% to 73.7% and the major types of anemia 
are IDA and ACD (Giannini & Martes, 2006).  
2.5.1 Iron deficiency anemia 
In addition to biochemical values (serum iron, total iron binding capacity, transferrin, 
ferritin), new indices of iron metabolism (for example soluble transferrin receptors or sTfR, 
sTfR-ferritin index, hepcidin, ferritin: transferrin receptor ratio, reticulocyte hemoglobin 
content or percentage of hypochromic red blood cells) may help with the assessment of IDA 
and ACD in IBD (Stein et al., 2010; Zhu et al., 2010). Traditionally, IDA is treated with oral 
iron supplementation. However in patients with UC, not only can oral iron cause more GI 
side effects, but it is also poorly absorbed in the gut secondary to mucosal inflammation and 
altered distribution. As a result, the strong oxidizing properties of the unabsorbed iron 
inside the gut lumen can exacerbate the UC (Zhu, Kaneshiro et al., 2010). Hence, parenteral 
iron therapy and erythropoietin have been advocated in the treatment of IDA in UC patients 
(Gomollon & Gisbert, 2009; Stein, Hartmann et al., 2010; Wilson, Reyes et al., 2004; Zhu, 
Kaneshiro et al., 2010). 
2.5.2 Anemia of Chronic Disease 
ACD, seen in patients with acute or chronic inflammation, is the second most common anemia 
in both the general and IBD population (Weiss & Goodnough, 2005). The pathogenesis of ACD 
is immune driven by cytokines and cells of the reticuloendothelial system. Erythropoiesis is 
decreased secondary to the chronic inflammation and corresponding anti-inflammatory 
treatments for IBD (Zhu, Kaneshiro et al., 2010). In UC, recombinant human erythropoietin is 
recommended for ACD and IDA if parenteral iron therapy is ineffective (Stein, Hartmann et 
al., 2010; Weiss & Goodnough, 2005; Zhu, Kaneshiro et al., 2010). 
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2.5.3 Autoimmune Hemolytic Anemia 
The association of autoimmune hemolytic anemia (AIHA) with UC is rare, occurring in less 
than 1% of cases. However, AIHA should be suspected in patients with anemia, painless 
jaundice, and unconjugated hyperbilirubinemia (Gumaste et al., 1989; Valderrama Rojas et 
al., 2003). The diagnosis of AIHA includes a positive direct Coombs test that detects IgG or 
complement absorbed onto red blood cells. However, studies have shown that 
approximately 1.82% of UC patients without signs of hemolysis can have a positive direct 
Coombs test (Valderrama Rojas, Rodriguez Gorostiza et al., 2003). Systemic steroids are the 
first line of therapy, produce remission in 21% to 50% of cases, and should be continued for 
3 weeks before being considered ineffective (Gumaste, Greenstein et al., 1989; Veloso et al., 
1991). For cases unresponsive to steroids, immunosuppressive therapy with agents such as 
cyclophosphamide or azathioprine and surgical intervention including splenectomy should be 
considered. A case report describes a patient with UC and AIHA in which 
immunosuppression with steroids and azathioprine was not successful in achieving remission. 
Ultimately, splenectomy was performed and the patient went into remission allowing her 
immunosuppressants to be discontinued (Wodzinski & Lawrence, 1985).  If the hemolysis is 
not responding to the aforementioned treatments, colectomy or total proctocolectomy are 
advisable and effective (Gumaste, Greenstein et al., 1989)(Sharma 2002). Thrombocytopenia 
with AIHA is known as Evan’s syndrome. A case report describes an association of Evan's 
syndrome with UC that responded to immunosuppressive therapy (Ucci et al., 2003). 
2.5.4 Other hematologic complications 
Agranulocytosis and thrombocytopenia have been reported to be associated with UC. This 
can be secondary to medication side effects: for example, sulfasalazine has been shown to 
cause agranulocytosis and mesalamine has been showed to cause thrombocytopenia (Farrell 
et al., 1999; Roddie et al., 1995). Immune-mediated neutropenia and thrombocytopenia have 
also been reported in UC (Kim et al., 1995). Idiopathic thrombocytopenic purpura (ITP), 
documented by various case reports to occur in patients with UC, is autoimmune in nature 
and treatment is similar to that of AIHA with steroids, splenectomy, and if necessary, 
colectomy (Mizuta et al., 2003; Yoshida et al., 1996). 
Various hematologic malignancies have been reported as UC complications and include: acute 
promyelocytic leukemia, acute myelogenous leukemia, chronic granulocytic leukemia, and 
myelodysplastic syndrome (Braverman & Bogoch, 1978; Fabry et al., 1980; Hebbar et al., 1997; 
Rosen & Teplitz, 1965). However, the pathogenesis of the association remains unclear (Fabry, 
Sachar et al., 1980; Hebbar, Kozlowski et al., 1997; Rosen & Teplitz, 1965; Suzuki et al., 1995). 
2.5.5 Vascular complications 
Venous thromboembolism (VTE) such as deep vein thrombosis (DVT) and pulmonary 
embolism (PE) are known complications of UC (Braverman & Bogoch, 1978). This is 
attributable to the hypercoagulable state associated with UC with patients often having 
active disease at time of VTE (Koutroubakis, 2005). Treatment is similar to that of patients 
without IBD. Arterial thrombosis is a rare complication of UC and sites of thrombosis 
involving radial, brachial and common carotid arterial thrombosis have been reported 
(Braverman & Bogoch, 1978; Mikroulis et al., 1999; Nogami et al., 2007). The pathogenesis of 
arterial thrombosis is related to increased fibrinogen levels, increased platelet counts, and 
decreased anti-thrombin III levels (Mikroulis, Antypas et al., 1999). Treatment with 
antithrombotic therapy can often worsen the UC and in patients who fail antithrombotic or 
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anticoagulation therapies, colectomy is often necessary (Mikroulis, Antypas et al., 1999; 
Nogami, Iiai et al., 2007). 
UC has been reported to be associated with several vasculitides including: Takayasu's 
arteritis and giant cell arteritis (Jacob et al., 1990; Kawashima et al., 1999; Shibata et al., 2002). 
Takayasu's arteritis is a granulomatous arteritis involving the aorta and its branches. 
Involvement of the common carotid artery will show typical tenderness of carotid artery, an 
early but pathognomonic symptom of Takayasu’s arteritis. MRI is helpful for the early 
diagnosis of Takayasu's arteritis (Kawashima, Koike et al., 1999). Giant cell arteritis is 
granulomatous arteritis involving medium and large-sized arteries. Giant cell arteritis, also 
known as temporal arteritis and cranial arteritis, usually presents with headache, blurred 
vision, and sometimes sensorineural deafness (Jacob, Ledingham et al., 1990). Biopsy of 
temporal artery is needed for definitive diagnosis of temporal arteritis. Both Takayasu's 
arteritis and Giant cell arteritis respond to steroids (Jacob, Ledingham et al., 1990; 
Kawashima, Koike et al., 1999; Shibata, Funayama et al., 2002). Early diagnosis is important 
as delayed treatment can lead to permanent loss of vision. 
2.6 Renal and genitourinary tract complications 
A significant number of UC patients can develop complications involving the kidney and 
genitourinary tract. These complications include urolithiasis, chronic renal disease, ureteral 
obstruction, fistulas, and renal cell carcinoma. 
2.6.1 Urolithiasis 
Kidney stones, usually composed of either calcium oxalate or uric acid, are more prevalent 
in UC patients than in the general population (Caudarella et al., 1993). UC patients, 
especially those who have undergone surgery, have been shown to have decreased urinary 
volume, pH, magnesium, and excretion of citrate, all of which are significant risk factors for 
renal stone formation. Dehydration from diarrhea during UC flares further increases one’s 
chance of developing nephrolithiasis. 
2.6.2 Chronic renal disease 
A statistically significant increased risk for renal disease is found in UC but not in CD 
patients (Bernstein et al., 2005). Reported chronic renal diseases associated with UC include: 
glomerulonephritis, immunoglobulin A nephropathy, nephrotic syndrome, idiopathic 
interstitial nephritis, drug-induced nephritis by mesalamine, NSAID induced nephropathy, 
type AA renal amyloidosis, or secondary amyloidosis (Basili et al., 2002; Skhiri et al., 1998; 
rStokke et al., 1976; Tokuyama et al., 2010). Kidney biopsy is indicated in order to confirm 
the diagnosis. 
Nephrotic syndrome as a complication of UC has been reported to be related to an 
underlying complement and immune disorder and usually responds favorably to steroid 
treatment. A case report documents rapid improvement in renal function after colectomy 
(Stokke, Teisberg et al., 1976). UC patients found to have micro- or macro-hematuria should 
receive a renal biopsy for possible immunoglobulin A nephropathy (Trimarchi et al., 2001). 
Many of these diagnoses can end in renal failure and may ultimately require hemodialysis. 
2.6.3 Ureteral obstruction 
Ureteral involvement has been reported to occur in 3-6% of IBD cases (Ruffolo et al., 2004). 
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Ureteral obstruction in UC can be caused by kidney stone or retroperitoneal inflammation 
and fibrosis. Intravenous pyelography (IVP) is used to diagnose non-calculous ureteral 
obstruction and is found in 14% of UC patients (Fleckenstein et al., 1977). These patients are 
initially asymptomatic, but chronic obstruction and lead to pyelonephritis, hydronephrosis, 
hypertension, and eventual loss of kidney function. Because occult ureteral stenosis without 
gastrointestinal symptoms may be present, the possibility of IBD should be raised in 
patients who present with isolated ureteral stenosis (Kruglik et al., 1977). Initial 
management focuses on medical treatment of UC, but nephrostomy tubes or ureteral stents 
are indicated to relieve any obstructions.  
2.6.4 Renal Cell Carcinoma 
Renal cell carcinoma (RCC), although relatively uncommon, has been documented to occur 
in UC patients. While the association is unclear, possible etiologies include genetic 
predisposition or immunosuppression from medications. Treatment usually requires 
surgical intervention including nephrectomy (Satsangi et al., 1996). 
2.7 Neurological complications 
Both central and peripheral neurological disorders have been reported to occur in patients 
with UC. These include strokes, cerebral sinus thrombosis, cerebral vasculitis, acute 
disseminated encephalomyelitis, multiple sclerosis, peripheral neuropathies, and many 
other disorders (Jose & Heyman, 2008). Neurological complications of UC can be 
differentiated into three major categories: cerebrovascular disease, cerebral vasculitis, and 
immune mediated neuropathy. (Pandian et al., 2004) 
2.7.1 Cerebrovascular disease 
Compared to venous thrombotic events such as DVT and pulmonary emboli, thrombotic 
events occurring in the CNS are relatively rare occurring in up to 7.5% of cases 
(Nudelman et al., 2010). Cerebral sinus thrombosis typically presents with headache, 
convulsions, hemiparesis, and/or other neurologic signs and diagnosis is made by MRI 
angiogram (Tsujikawa et al., 2000). Because untreated cerebral sinus thrombosis can result 
in fatal cerebral edema and herniation, rapid diagnosis and treatment aimed to reduce 
intracranial pressure with a combination of steroids, diuretics, anticoagulants, and 
antithrombotic therapy is essential (Nudelman, Rosen et al., 2010; Tsujikawa, Urabe et al., 
2000).  
Cerebral arterial thrombosis is also a rare complication of UC, but has been described in 
young patients without any other significant risk factors of cerebral vascular accidents 
such as hyperlipidemia, cardiac arrhythmia, or carotid artery disease (Katsanos & 
Tsianos, 2002). Unfortunately, due to the rarity of cases, there are no official guidelines on 
the treatment of strokes in patients with IBD. Case reports have documented that arterial 
thrombotic events in UC patients is often associated with severe pan-colonic disease and 
generally carries a poor prognosis (Novotny et al., 1992). Colectomy may be necessary in 
these patients. 
2.7.2 Cerebral vasculitis 
Cerebral vasculitis is another complication of UC and can manifest as seizures and severe 
headaches (Masaki et al., 1997; Nomoto et al., 2006). Diagnosis is typically made with MRI 
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digital subtraction angiogram that shows a “beaded” appearance with multiple areas of 
irregularities of the intracerebral arteries. Treatment is similar to that of systemic vasculitis 
and usually involves steroids and/or immunosuppressants (Nelson et al., 1986; Nomoto, 
Nagao et al., 2006).  
2.7.3 Immune mediated neuropathy 
An association between UC and multiple sclerosis (MS) has been found both within families 
and within individuals (Hoffmann & Kruis, 2004). MS affects UC more than CD patients and 
the prevalence of MS in IBD patients is about 3.7 times more than seen in the average 
(Kimura et al., 2000). There are clearly common factors between IBD and MS, but more 
research is necessary to establish specific relationships between the two disorders (Pandian, 
Pawar et al., 2004). Management of these patients including diagnosis and treatment is 
generally similar to patients without UC (Pandian, Pawar et al., 2004).  
Other rare neurological complications of UC that have been reported include: acute 
disseminated encephalomyelitis, optic neuritis, sensorineural hearing loss, myelopathy, 
peripheral polyneuropathy, Guillain-Barre syndrome, and myasthenia gravis (Gondim et 
al., 2005; Kanra et al., 2002; Krystallis et al., 2010; Lossos et al., 1995; Scheid & Teich, 2007; 
Tan, 1974; Yesilova et al., 2006). Many of these complications are autoimmune in nature and 
respond to steroids and/or immunosuppressive therapy. 
2.8 Pulmonary complications 
A variety of pulmonary complications associated with UC have been well documented and 
reported in medical and scientific literature. Virtually any part of the respiratory system can 
be involved and the pulmonary complications can be classified into airway, parenchymal, 
vascular, thromboembolic, and pleural disease. 
2.8.1 Airway disease 
Almost any part of the airway ranging from the trachea to the bronchi and bronchioles, can 
be associated with UC with the most common complications involving the bronchi 
(Higenbottam et al., 1980). Bronchial involvement may present as a chronic persistent cough 
with mucopurulent production suggesting chronic bronchitis or bronchiectasis (Gibb et al., 
1987). In general, these symptoms do not respond to antibiotics, but do respond to inhaled 
steroids (Higenbottam, Cochrane et al., 1980). Studies have shown that in UC patients, 
colonic and pulmonary flares often parallel each other, suggesting a common embryonic 
origin of the colonic and pulmonary epithelium (Higenbottam, Cochrane et al., 1980; Wilcox 
et al., 1987). Furthermore, the histopathology of sclerosing cholangitis, another EIM of UC, 
has been shown to be quite similar to that of the airway inflammation associated with UC 
(Janssen et al., 2006). 
Tracheal involvement can present as cough, hoarseness, dyspnea or even stridor due to 
inflammation and stenosis in subglottic or upper tracheal area. Depending on the severity of 
the inflammation and degree of respiratory compromise, systemic steroids and sometimes 
endotracheal intubation may be indicated (Janssen, Bierig et al., 2006; Rickli et al., 1994). 
Less frequently seen in UC patients is bronchiole and small airways inflammation 
manifested as constrictive bronchiolitis or bronchiolitis obliterans with organizing 
pneumonia (BOOP) (Ward et al., 1999). Constrictive bronchiolitis is defined as concentric 
fibrosis in the bronchiolar submucosal layer with continuous external circular scarring 
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(Epler, 2007). BOOP is an inflammatory disease involving the terminal bronchiole and 
alveoli (lung parenchyma), and has been reported to be associated with UC. Symptoms seen 
with small airway involvement include cough, sputum production, wheezing, dyspnea, 
fever, flu-like symptoms, and pleuritic chest pain. These symptoms can manifest acutely or 
in chronic fashion and systemic steroids are indicated in the treatment of small airway 
inflammation. 
Diagnosis 
1. Routine laboratory tests: Sputum culture can rule out a respiratory infection. Observing 
peripheral eosinophilia on complete blood count can help differentiate inflammation 
from infection. Chest X-ray may show diffuse narrowing of the trachea in tracheal 
stenosis, thickening of the bronchial wall in bronchiectasis, or ground glass opacities in 
BOOP (Epler, 2001; Gibb, Dhillon et al., 1987; Janssen, Bierig et al., 2006). 
2. Pulmonary function tests: An obstructive pattern is usually seen in large airway 
inflammation while a restrictive pattern is usually seen in small airway or parenchymal 
inflammation. Patients with inflammation affecting various parts of the airway and 
parenchyma can have mixed patterns on pulmonary function tests (Gibb, Dhillon et al., 
1987). In patients with upper airway obstruction, flow-volume loops will show showing 
flattening of the inspiratory and expiratory limbs (Janssen, Bierig et al., 2006). A low 
lung diffusing capacity for carbon monoxide (DLco) can help to diagnose small airway 
inflammation such as BOOP or parenchymal disease such as interstitial lung disease. 
3. CT scan: CT scans, especially High Resolution CT (HRCT) scans are more sensitive than 
plain chest films in differentiating between the pulmonary complications of UC. 
Irregular narrowing of the trachea or main bronchi can be seen in large airway 
involvement, thickened bronchial walls and dilated airways with mucoid impaction can 
be seen with bronchial involvement, and bilateral consolidation and peripheral 
(pleural-based) ground glass opacities are observed in BOOP (Epler, 2001; Garg et al., 
1993; Spira et al., 1998; Wilcox, Miller et al., 1987). 
4. Bronchoscopy: Bronchial epithelial biopsy can help diagnose tracheal stenosis with 
extensive inflammation with granulation tissue, basal reserve cell hyperplasia, 
thickening of the basement membrane, and submucosal inflammation (Gibb, Dhillon et 
al., 1987; Janssen, Bierig et al., 2006). 
5. Surgery: Open lung biopsy or video-assisted thoracoscopic (VATS) procedure with 
biopsy may be needed to establish a diagnosis of BOOP or interstitial lung disease 
(Epler, 2001). 
2.8.2 Lung parenchymal disease 
BOOP, a disorder with both airway and parenchymal involvement, has been discussed 
under the airway disease section. Interstitial lung disease as a pulmonary complication of 
UC is extremely rare and is usually steroid-responsive, but cases of mortality have been 
reported (Marten et al., 2005). In a case report, a patient with UC was described to present 
with dyspnea and fatigue, but unlike BOOP, cough or fever was absent. Physical 
examination revealed inspiratory crackles and chest x-ray revealed reticular densities in the 
mid- to lower lung field bilaterally. CT scan revealed honeycombing and ground glass 
opacification with traction bronchiectasis and bronchiolectasis in similar lung field. 
Pulmonary function test revealed restriction pattern with reduced DLco and the patient 
ultimately developed respiratory failure requiring mechanical ventilation and passed away 
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from acute right ventricular failure (Marten, Fend et al., 2005). Pulmonary infiltrates with 
eosinophilia (PIE syndrome) is a recognized pulmonary complication of UC and has been 
documented to occur in patients receiving and not receiving sulfasalazine/mesalamine 
therapy (Camus et al., 1993; Saltzman et al., 2001). Typical chest x-ray appearance of PIE is 
peripheral homogenous nonsegmental air-space infiltrate or a "reverse pulmonary edema" 
pattern (Saltzman, Rossoff et al., 2001). The patient presents with dry cough, wheezing, 
fever, night sweat, and malaise. Peripheral blood and bronchoalveolar lavage can 
demonstrate eosinophilia. Systemic steroid treatment causes prompt and sustained 
resolution of clinical and radiographic abnormalities (Saltzman, Rossoff et al., 2001). 
Necrobiotic nodules (sterile abscesses) are rare pulmonary complications of UC.  Patients 
usually present with high fever and constitutional symptoms. The lesions show PMNs and 
fibrin with necrosis, a similar pattern seen in PG, a dematologic complication of IBD (Camus, 
Piard et al., 1993; Warwick et al., 2009). Chest X-ray can show multiple cavitary and non-
cavitary nodules. In 2 case reports, therapy with steroids with or without cyclophosphamide 
successfully produced remission without relapse (Camus, Piard et al., 1993). 
2.8.3 Vascular disease 
Pulmonary vasculitis is a rare complication of UC (Black et al., 2007; Forrest & Shearman, 
1975; Hilling et al., 1994; Isenberg et al., 1968). Patients can present with fever, dyspnea, or 
cough with blood-tinged sputum (Forrest & Shearman, 1975; Hilling, Robertson et al., 1994). 
Other vascular diseases associated with UC include Wegener granulomatosis, Churg-
Strauss syndrome, and microscopic polyangiitis(Black, Mendoza et al., 2007). Nodular lung 
lesions can be seen in pulmonary vasculitis and Wegener's granulomatosis and are usually 
responsive to systemic steroids (Black, Mendoza et al., 2007; Forrest & Shearman, 1975; 
Hilling, Robertson et al., 1994; Isenberg, Goldstein et al., 1968; Stebbing et al., 1999). 
2.8.4 Vascular thromboembolic disease 
The incidence of VTE is about 3 to 4 times higher for patients with IBD in comparison with 
controlled age-matched groups (Bernstein et al., 2001a; Miehsler et al., 2004; Stebbing, Askin 
et al., 1999). The age-adjusted incidence ratios of UC compared to age-matched population 
was 2.8 for DVT and 3.6 for pulmonary embolism (PE) (Bernstein, Blanchard et al., 2001). 
IBD patients have increased risk factors for thromboembolism secondary to the underlying 
disease process or its associated complications including dehydration, inactivity, 
hospitalization, surgery, and central venous catheterization. However, up to 1/3 of VTE 
events occur in patients while the underlying disease process is quiescent, suggesting that 
there are additional risk factors unrelated to disease activity or accompanying therapies 
(Stebbing, Askin et al., 1999; Tsiolakidou & Koutroubakis, 2008). The following genetic 
factors have been suggested to increase the incidence of VTE in IBD patients: factor V 
Leiden, factor II (prothrombin, G20210A), methylenetetrahydrofolate reductase gene 
mutation (MTHFR, 6777T), plasminogen activator inhibitor type 1 (PAI-1) gene mutation 
and factor XIII (val34leu) (Tsiolakidou & Koutroubakis, 2008). The symptoms, diagnosis and 
treatment of DVT and PE in UC are similar to patients without IBD. 
2.8.5 Pleural disease 
Pleural and pericardial complications of IBD in the form of serositis, pleural effusions, 
pleuritis, pericarditis, pleuro-pericarditis or myo-pericarditis are uncommon (Tsiolakidou & 
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Koutroubakis, 2008). When they do occur, they are usually diagnosed in young male 
patients with UC (Camus, Piard et al., 1993; Stebbing, Askin et al., 1999). The pleural 
effusion is almost always unilateral and exudative in nature. The symptoms and diagnosis 
of serositis are similar to other patients without UC and the treatment of serositis includes 
steroid and NSAIDs such as aspirin and Indocin (Stebbing, Askin et al., 1999). 
2.9 Cardiac complications 
In general, cardiovascular involvement with UC is uncommon, but complications such as 
intracavitary thrombosis, endocarditis, myocarditis, pericarditis, coronary artery disease, 
arrhythmias, and heart failure have been described in case reports (Katsanos & Tsianos, 
2002).  
2.9.1 Thrombosis 
Intracavitary thrombosis, diagnosed by echocardiogram, has been reported to occur in the 
right atrium and left ventricle of UC patients (Saleh, 2010; Sasvary et al., 1996). Early 
diagnosis and treatment is essential as RA thrombus can lead to PE and LV thrombus can 
lead to systemic embolism. 
2.9.2 Endocarditis 
In UC patients, endocarditis can occur as a result of bacteremia, prolonged total parenteral 
nutrition (TPN) usage, or immunosuppression (Katsanos & Tsianos, 2002). Responsible 
organisms include streptococcus bovis, enterococcus faecium, and candida albicans 
(Christakis et al., 2007; Moshkowitz et al., 1992). Other complications that have been 
reported of endocarditis in UC patients include cerebral infarction and mitral valve leaflet 
aneurysm for which surgical intervention is indicated (Katsanos & Tsianos, 2002; Tomomasa 
et al., 1993). 
2.9.3 Myocardial Involvement 
Although relatively rare, myocardial involvement in UC patients compared with the general 
population has an incidence ratio of 2.6 (Sorensen & Fonager, 1997). A majority of cases in 
UC patients with myocardial involvement is complicated by pericarditis or pleural effusion. 
Prolonged corticosteroid use has been implicated in the cause of hypertrophic 
cardiomyopathy and mesalamine has been reported to cause myocarditis and 
perimyocarditis (Katsanos & Tsianos, 2002).  
Case reports of acute myocardial infarction have been documented to occur during flares 
(Efremidis et al., 1999). The pathogenesis behind this ischemia is presumed to be reversible 
vasoconstriction of varying severity decreasing blood flow to myocardial tissue (Katsanos & 
Tsianos, 2002).  
2.9.4 Pericarditis 
The most commonly reported cardiac complication of UC is pericarditis which can be 
caused by drugs (5-aminosalicylic acid, mesalamine, azathioprine), pericardio-colonic 
fistulas, or idiopathic mechanisms (Katsanos & Tsianos, 2002). Both acute and chronic 
pericarditis with and without cardiac tamponade have been reported (Cappell & Turkieh, 
2008; Dubowitz & Gorard, 2001). Drug induced pericarditis typically resolves after omission 
of the offending drug and treatment with NSAIDs is effective. Cardiac tamponade is a rare, 
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but life threatening complication of UC that can be diagnosed by echocardiogram or cardiac 
catheterization. Treatment includes emergent pericardiocentesis and pericardiectomy is 
indicated for recurrent pericardial effusion and chronic constrictive pericarditis (Cappell & 
Turkieh, 2008; Rezaie et al., 2010). 
2.9.5 Valvular Involvement 
Valvular involvement in UC is relatively common and can manifest as endocardium and 
aortic root involvement. Aortic and mitral valve involvement may require surgical 
replacement, but generally carries with good outcomes and prognosis (Katsanos & Tsianos, 
2002).  
2.9.6 Arrhythmias 
Various types of cardiac arrhythmia have been reported to occur in UC, including 
Wenckebach, complete heart block, atrial fibrillation, supraventricular tachycardia, 
ventricular tachyarrhythmia, and mesalamine related sinus bradycardia (Katsanos & 
Tsianos, 2002). A permanent pacemaker is indicated for complete heart block (Maeder, 
1996). Hypomagnesemia is frequently seen in UC due to ongoing fecal losses and this can 
lead to ventricular tachycardia. Treatment with magnesium infusion is effective (Levine et 
al., 1982). Interestingly, in patients with no prior cardiac history or electrolyte balance, QT 
intervals were found to be significantly higher in UC than CD, suggesting an increased risk 
of dangerous arrhythmias (Curione et al., 2010).  
2.9.7 Heart failure 
Heart failure in UC can be acute (acute myocardial infarction, myocarditis, cardiac 
tamponade, valvular deterioration) or chronic (myocardium or valvular involvement, heart 
muscle atrophy with TPN and prolonged steroid use) (Katsanos & Tsianos, 2002). Aortic 
valve insufficiency can cause heart failure and cardiogenic shock (Lidon & Ariza, 1993). 
Sudden cardiac arrest in UC patients can be secondary to acute myocardial infarction, 
cardiogenic shock, or ventricular arrhythmias (Katsanos & Tsianos, 2002).  
3. Conclusion 
UC is a systemic disease, since its clinical manifestations can affect not only the bowel, but 
can also involve almost any organ including the skin, eyes, liver, musculoskeletal 
cardiovascular, hematologic, and renal systems (Table 1). These EIM can influence both 
morbidity and mortality. Most of the patients with IBD associated EIMs have extensive 
colitis and family history of the disease. With the exception of PSC, AS, PG, and type 2 
arthritis, extraintestinal complications tend to follow the clinical course of IBD. Awareness 
and understanding of the disease manifestations extrinsic to the gastrointestinal tract are 
essential in the management of IBD patients. 
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Common Manifestations    
Organ System Features CD or UC 
IBD Activity 
Correlation 
Dermatologic     
Erythema nodosum 
 
Painful, raised subcutaneous lesions on 
extensor surfaces 
Both Yes 
 
 
Conservati
rest, NS
Treatm
Pyoderma gangrenosum 
 
 
Early: noninfectious pustules and 
nodules 
Late: Painful ulcers that can be shallow 
or deep 
Both No 
 
Corticoster
Cyclospor
Biologics 
Hyperbaric oxyg
Surgery 
Aphthous stomatitis 
Small, round, painful ulcers in oral 
mucosa 
Both Yes 
Glucocorticoids 
Immuno
Treatm
Pyostomatitis vegetans 
Hyperplastic folds of oral mucosa with 
small abscesses and erosions 
Both, but 
especially UC 
Yes, occurs 
prior to flares 
Glucocorticoids and 
immun
success
Colectomy
remission
Hepatopancreatobiliary     
Primary Sclerosing Cholangitis 
Progressive inflammatory destruction of 
bile ducts 
Chronic intermittent obstructive jaundice 
Abdominal pain, pruritus, fatigue, fever, 
weight loss 
Both, but 
more common 
in UC 
No 
Ursodeoxycholic A
Endoscopic I
stent pla
Liver tran
Primary Biliary Cirrhosis 
Progressive cholestatic liver disease 
Pruritus, jaundice, skin pigmentation, 
fatigue, abominal pain 
Both 
Chronic disease 
progression 
Choles
Ursodeoxycholic A
ERCP for bile dr
 
w
w
w
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Common Manifestations    
Organ System Features CD or UC 
IBD Activity 
Correlation 
Autoimmune Hepatitis 
Acute/chronic hepatitis or cirrhosis 
Fever, right upper quadrant pain, 
jaundice 
Both No 
Glucocorticoids 
Azathi
Liver transpla
Pancreatitis 
Abdominal pain, nausea/vomiting 
Acute and chronic: idiopathic, gallstones, 
PSC, medication induced 
Autoimmune: obstructive jaundice 
Both Controversial 
Treatment o
Autoimm
Musculoskeletal Basic Features:  Clinical or Histologic   
Peripheral arthritis 
Pain, heat, swelling, decreased mobility 
in affected joint.  
Non-deforming, non-erosive 
Worse in AM, improves with activity 
Type 1: acute, pauci-articular (<5 joints), 
asymmetrical, self-limiting 
Type 2: poly-articular (≥ 5 joints), 
migratory arthritis, chronic with 
relapsing/remitting course 
Both, more 
common in 
CD 
Type 1: Yes 
Type 2: No 
Type 1: Treatm
Type 2: COX-
immun
inhibi
Both: Sy
therapy, i
Axial Arthritis (Sacroiliitis and 
Ankylosing Spondylitis) 
Back pain 
Back stiffness in morning or after rest 
Both No 
Intens
Glucocorticoids, sulfasalazine, 
methotrexate, T
Osteoporosis 
Bone pain 
Increased fracture risk 
Both, more 
severe in CD 
than UC 
Indirectly 
related to 
nutrition, 
absorption, and 
treatment 
Sympto
Medical: Calcium
bisphosp
Surgical: correction of 
Polymyositis/Dermatomyositis 
Muscle pain/weakness 
Elevated serum CPK 
Both No 
Glucocorticoids 
5-ASA 
w
w
w
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Common Manifestations    
Organ System Features CD or UC 
IBD Activity 
Correlation 
Orbital Myositis 
Sudden orbital pain 
Periorbital/eyelid edema 
Diplopia 
Exophthalmos 
Conjunctival injection 
Rare in both No Glucocorticoids 
Gastrocnemius Myalgia 
Syndrome 
Calf tenderness 
Both, more 
common in 
CD 
No Glucocorticoids 
Ocular     
Episcleritis 
Acute onset of injection, irritation of eye 
Vision typically not affected 
Both Yes 
Topical steroids 
Treatm
Uveitis 
Photophobia, blurred vision, pain, 
conjuctival injection 
Both 
Unpredictable, 
but can parallel 
luminal IBD 
activity 
Topical steroids 
Mydriatics 
Inflixim
Scleritis 
Deep eye pain with radiation to 
eyebrows, cheeks, temples 
Eye redness, tearing, photophobia, 
blurred vision 
Blindness 
Both 
May precede or 
follow IBD 
diagnosis 
Oral s
NSAIDS
Immuno
Surgical repair 
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Less Common Manifestations    
Organ System Features CD or UC 
IBD Activity 
Correlation 
Therapy
Hematologic     
Iron deficiency anemia 
UC: more often secondary to blood loss 
CD: more often secondary to poor 
absorption 
Both, more 
common in 
UC 
Yes 
Iron (paren
therapy)
Erythropoietin if 
Anemia of chronic disease 
Secondary to inflammatory cytokines 
and/or low erythropoietin 
Both, more 
common in 
CD 
Yes Erythropoietin + 
Megaloblastic anemia  From folic acid or B12 deficiency 
Both, more 
common in 
CD (ileal 
disease/resec
tion) 
Yes 
Intram
B12 
Folic A
Autoimmune hemolytic 
anemia (AIHA) 
Anemia, painless jaundice, 
unconjugated hyperbilirubinemia 
Both, more 
common in 
UC 
Controversial 
Steroids 
Splenectomy
Immuno
Colectomy
Idiopathic Thrombocytopenic 
Purpura (ITP) 
Petechiae, purpura, epistaxis 
Both, more 
common in 
UC 
No 
Steroids 
Immuno
Splenectomy
Colectomy
Evan's Syndrome 
ITP + AIHA 
Autoantibodies to platelets and RBCs 
Both, more 
common in 
UC 
No Treatm
Vascular     
Venous Thromboembolism 
Deep vein thrombosis 
Pulmonary embolism 
Both Yes 
Similar anticoagulation treat
for patient
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Less Common Manifestations    
Organ System Features CD or UC 
IBD Activity 
Correlation 
Therapy
Arterial Thrombosis 
Thrombosis of radial, brachial and 
common artery 
Both Yes 
Antith
therapies
Colectomy
 
Renal     
Urolithiasis 
Sudden, severe, colicky pain in back, 
flank, or groin 
Nausea/vomiting 
Both No 
Narcotics
Lithotripsy
Surgery 
 
Chronic Renal Disease 
Glomerulonephritis, immunoglobulin 
A nephropathy, nephrotic syndrome, 
interstitial nephritis, drug-induced 
nephritis, renal amyloidosis 
UC Variable 
Hemodialys
renal failure 
Neurological     
Cerebrovascular Disease 
(Cerebral sinus/arterial 
thrombosis) 
Headache, convulsions, hemiparesis, 
focal neurological signs 
Both No 
Sinus th
reduction
anticoagulan
Arterial thrombo
guidelines, colectom
Cerebral Vasculitis 
Seizures 
Severe headaches 
"Beaded" appearance of intracerebral 
arteries with MRI 
Both unclear 
Steroids 
Immuno
Anticoagulation 
Immune Mediated 
Neuropathy (Multiple 
Sclerosis) 
Diplopia, numbness, slurred speech, 
other neurological signs  
Both unclear 
Steroids 
Immuno
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Less Common Manifestations    
Organ System Features CD or UC 
IBD Activity 
Correlation 
Therapy
Pulmonary  
In general 
UC > CD 
  
Upper Airway Disease 
(Epiglottitis, 
Laryngotracheitis, Subglottic, 
or Tracheal stenosis) 
Cough, hoarseness, dysphonia, 
dyspnea, stridor 
Both No 
Inhaled steroids 
System
Laser ablation
obstruction 
Large Airway Disease 
(Chronic bronchitis, 
Bronchiectasis) 
Cough, mucopurulent sputum 
production 
Both No 
Inhaled steroids 
Low dose
Small Airway Disease 
(Constrictive bronchiolitis) 
Cough, sputum, dyspnea, wheezing, 
fever 
Concentric fibrosis in bronchiolar 
submucosal layers with continuous 
external circular scarring inflammation 
in terminal bronchiole 
Both No 
Inhaled steroids 
Low dose
 Small Airway and Lung 
Parenchymal Disease (BOOP) 
Dry cough, dyspnea, fever, wheezing, 
pleuritic chest pain, flu-like symptoms 
Both, more 
common in 
UC 
No 
High do
System
Interstitial Lung Disease Dyspnea, fatigue Both No 
Oral steroids with or without other 
immun
Pulmonary infiltrates with 
eosinophilia (PIE) 
Dry cough, wheezing, fever, chest 
tightness, night sweats, malaise 
Eosinophilia in blood and 
bronchoalveolar lavage 
Both No Oral st
Lung necrobiotic nodules 
(Sterile abscesses) 
High fever, constitutional symptoms 
PMNs and fibrin with necrosis, absence 
of giant cells, vasculitis, or capillaritis 
Both, more 
common in 
UC 
No 
Oral steroids with or without 
cyclophosp
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Less Common Manifestations    
Organ System Features CD or UC 
IBD Activity 
Correlation 
Therapy
Pulmonary Vasculitis 
Fever, dyspnea, cough, blood-tinged 
sputum 
Nodular density on lung biopsy 
Both No Oral st
Pleural Effusion/Pleuritis 
Dyspnea, pleuritic chest pain 
Unilateral and exudative effusion 
Both No 
Steroids 
NSAIDs
Therapeutic thoracentesis 
Cardiac     
Intracavitary Thrombosis 
RA Thrombosis: pulmonary embolism 
LV Thrombosis: cerebrovascular event 
Both No Anticoagulation 
Infectious endocarditis 
Septicemia, related to TPN catheters 
and immunosuppressive therapy 
Both, more 
common in 
CD 
No 
Antibi
Valvular replace
Myocarditis (idiopathic, drug 
induced, selenium deficiency) 
Asymptomatic 
Chest pain, dyspnea 
Both, more 
common in 
UC 
No 
Withdrawal of offendi
Treatment o
Selenium supplem
Myocardial Infarction 
Angina, chest pain, diaphoresis 
Usual pathophysiologic mechanisms 
and risk factors 
Ischemia secondary to reversible 
vasoconstriction 
Both Yes 
Steroids 
Treatm
Treatment o
Pericarditis 
Pleuritic chest pain, fever, dyspnea, 
cough 
Both No 
Omissio
NSAIDs
Pericardiocen
tamponade
Pericardiectomy for 
pericarditis 
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Less Common Manifestations    
Organ System Features CD or UC 
IBD Activity 
Correlation 
Therapy
Valvular Involvement (from 
endocarditis or aortitis) 
Aortic regurgitation, mitral 
regurgitation, tricuspid regurgitation, 
mitral valve aneurysm 
Both No 
Treat underlying
Valvular replacement for co
cases 
Cardiac Arrhythmia 
Various types including Wenckebach, 
complete heart block, atrial fibrillation, 
SVT, etc. 
Both No 
Treat the arrhyt
Magn
Pe
hea
Heart Failure 
Acute: AMI, myocarditis, tamponade, 
valvular deterioration 
Chronic: myocardium or valvular 
involvement, myocardial atrophy due 
to prolonged TPN or steroid use 
Both No Treat underlying
Cardiac Related Sudden 
Death 
Sudden AMI, cardiogenic shock, 
cardiac tamponade, or arrhythmia 
Both No Treat underlying
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